Scottsdale 11/12/2015 8:00:00 PM
News / Stocks

QualityStocks News - Avant Diagnostics (AVDX) Leading an Evolution in Early Detection of Ovarian Cancer

QualityStocks would like to highlight Avant Diagnostics, Inc. (OTC: AVDX), a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.

In the company’s news,

Avant Diagnostics is a medical technology company at the forefront of driving an evolution in the screening of ovarian cancer. Its focus is centered on bringing to market innovative diagnostic tests based upon the completion of the human genome sequencing project. The company endeavors in developing a refined screening test for diagnosing ovarian cancer by way of OvaDx – the market’s first large-panel biomarker screening test for this deadly disease.

OvaDx® is considered to be an advanced diagnostic test that measures the activation of the immune system in response to ovarian tumor cell development. Patient sera are applied to OvaDx® microarrays which enable binding between proteomic biomarkers in the patient samples and capture agents on the microarrays. The microarrays are washed and scanned to produce a digital readout for each serum sample, and the data are quantified and analyzed in software to generate the test results.

Medical findings in genetic research offer extensive opportunities for impacting both the diagnosis and treatment of critical diseases. It focusses on identifying variations in specific genes in the genome, variations which reveal individual characteristics, including the state of the disease or its statistical characteristics. Tests of this nature that detect diseases at early stages in their progression and thus offer different options for earlier treatments resulting in better outcomes for the patient. As an additional result, medical providers benefit by way of significant cost savings by avoiding costly treatments traditionally reserved for cancer in its later stages.

ADVX’s discovery path is a result of a decade of genetic and physiological research. The company concentrates on capitalizing on the human immune system for early detection. The result, OvaDx, delivers a large panel of refined markers for high sensitivity. The company’s OvaDx markers and kits are proprietary, include patented manufacturing technology, and an exclusive, worldwide license. Upon FDA 510(k) clearance, Avant intends to sell or license OvaDx®. Avant intends to utilize its public company stage to expand its portfolio of diagnostic tests in the future.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit  

To connect with QualityStocks via Facebook, please visit

To connect with QualityStocks via Twitter, please visit

Please read FULL disclaimer on the QualityStocks website:   

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.